메뉴 건너뛰기




Volumn 30, Issue 6, 2014, Pages 1095-1106

A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

Author keywords

Albiglutide; Diabetes mellitus Type 2; Glucagon like peptide 1; Japanese

Indexed keywords

ALBIGLUTIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C PROTEIN, HUMAN;

EID: 84900818069     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.896327     Document Type: Article
Times cited : (27)

References (32)
  • 1
    • 84900834246 scopus 로고    scopus 로고
    • The global burden. Brussels, Belgium: International Diabetes Federation [Last accessed 29 October 2013]
    • The global burden. Brussels, Belgium: International Diabetes Federation, 2012. Available at: http://www.idf.org/diabetesatlas/5e/the-global-burden [Last accessed 29 October 2013]
    • (2012)
  • 2
    • 84900827235 scopus 로고    scopus 로고
    • The World Health Report Geneva Switzerland: World Health Organization 2002 [Last accessed 29 October 2013]
    • The World Health Report 2002. Geneva, Switzerland: World Health Organization, 2002. Available at: http://www.who.int/whr/2002/en/whr02-en.pdf [Last accessed 29 October 2013]
    • (2002)
  • 3
    • 84900806311 scopus 로고    scopus 로고
    • Outline for the Results of the National Health and Nutrition Survey Japan Tokyo, Japan: Ministry of Health, Labour and Welfare 2007 [Last accessed 29 October 2013]
    • Outline for the Results of the National Health and Nutrition Survey Japan, 2007. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2007. Available at: http://www.nih.go.jp/eiken/english/research/pdf/nhns2007.pdf [Last accessed 29 October 2013]
    • (2007)
  • 4
    • 3042672692 scopus 로고    scopus 로고
    • Insulin secretion and insulin sensitivity at different stages of glucose tolerance: A cross-sectional study of Japanese type 2 diabetes
    • Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004;53:831-5
    • (2004) Metabolism , vol.53 , pp. 831-835
    • Fukushima, M.1    Usami, M.2    Ikeda, M.3
  • 5
    • 3042569974 scopus 로고    scopus 로고
    • Primacy of beta-cell dysfunction in the development of hyperglycemia: A study in the Japanese general population
    • Katakura M, Komatsu M, Sato Y, et al. Primacy of beta-cell dysfunction in the development of hyperglycemia: a study in the Japanese general population. Metabolism 2004;53:949-53
    • (2004) Metabolism , vol.53 , pp. 949-953
    • Katakura, M.1    Komatsu, M.2    Sato, Y.3
  • 6
    • 79959449171 scopus 로고    scopus 로고
    • Body mass index and diabetes in Asia: A cross-sectional pooled analysis of 900, 000 individuals in the Asia cohort consortium
    • Boffetta P, McLerran D, Chen Y, et al. Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900, 000 individuals in the Asia cohort consortium. PLoS One 2011;6:e19930
    • (2011) PLoS One , vol.6
    • Boffetta, P.1    McLerran, D.2    Chen, Y.3
  • 7
    • 67651146970 scopus 로고    scopus 로고
    • Tokyo, Japan: Japan Diabetes Society [Last accessed 29 October 2013]
    • Treatment Guide for Diabetes, 2007. Tokyo, Japan: Japan Diabetes Society; 2007. Available at: http://www.jds.or.jp/modules/en/index.php?content- id35 [Last accessed 29 October 2013]
    • (2007) Treatment Guide for Diabetes, 2007
  • 8
    • 0037045845 scopus 로고    scopus 로고
    • Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study
    • Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30
    • (2002) Lancet , vol.359 , pp. 824-830
    • Zander, M.1    Madsbad, S.2    Madsen, J.L.3
  • 9
    • 0036828227 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
    • Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-408
    • (2002) Endocrinology , vol.143 , pp. 4397-4408
    • Farilla, L.1    Hui, H.2    Bertolotto, C.3
  • 10
    • 0029907680 scopus 로고    scopus 로고
    • Effects of subcutaneous gluca-gon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
    • Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous gluca-gon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-53
    • (1996) Diabetologia , vol.39 , pp. 1546-1553
    • Nauck, M.A.1    Wollschlager, D.2    Werner, J.3
  • 11
    • 78650903000 scopus 로고    scopus 로고
    • GIP and GLP-1, the two incretin hormones: Similarities and differences
    • Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig 2010;1:8-23
    • (2010) J Diabetes Investig , vol.1 , pp. 8-23
    • Seino, Y.1    Fukushima, M.2    Yabe, D.3
  • 12
    • 84878360808 scopus 로고    scopus 로고
    • Glucose-dependent insulinotropic polypeptide and gluca-gon-like peptide-1: Incretin actions beyond the pancreas
    • Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and gluca-gon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 2013;4:108-30
    • (2013) J Diabetes Investig , vol.4 , pp. 108-130
    • Seino, Y.1    Yabe, D.2
  • 13
    • 0037241085 scopus 로고    scopus 로고
    • Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
    • Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 220-224
    • Vilsboll, T.1    Agerso, H.2    Krarup, T.3
  • 14
    • 0027215348 scopus 로고
    • Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide his-tidine methionine and is responsible for their degradation in human serum
    • Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide his-tidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35
    • (1993) Eur J Biochem , vol.214 , pp. 829-835
    • Mentlein, R.1    Gallwitz, B.2    Schmidt, W.E.3
  • 15
    • 84900818947 scopus 로고    scopus 로고
    • Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc. [Last accessed 29 October 2013]
    • Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc., 2011. Available at: http://documents.byetta.com/Byetta-PI.pdf [Last accessed 29 October 2013]
    • (2011)
  • 16
    • 77953744676 scopus 로고    scopus 로고
    • Plainsboro NJ: Novo Nordisk Inc. [Last accessed 29 October 2013]
    • Victoza [package insert]. Plainsboro NJ: Novo Nordisk Inc. 2010. Available at: http://www.novo-pi.com/victoza.pdf [Last accessed 29 October 2013]
    • (2010) Victoza [Package Insert]
  • 17
    • 79953170013 scopus 로고    scopus 로고
    • Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
    • Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Investig 2010;1:56-9
    • (2010) J Diabetes Investig , vol.1 , pp. 56-59
    • Yabe, D.1    Kuroe, A.2    Lee, S.3
  • 18
    • 79956200849 scopus 로고    scopus 로고
    • Albiglutide, Glucagon-like peptide GLP-1 receptor agonist, treatment of type 2 diabetes
    • Rosenstock J, Stewart MW. Albiglutide. Glucagon-like peptide GLP-1 receptor agonist, treatment of type 2 diabetes. Drugs Future 2010;35:701-12
    • (2010) Drugs Future , vol.35 , pp. 701-712
    • Rosenstock, J.1    Stewart, M.W.2
  • 19
    • 70349664297 scopus 로고    scopus 로고
    • Potential of albiglutide, a long-Acting GLP-1 receptor agonist, in type 2 diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
    • Rosenstock J, Reusch J, Bush M, et al. Potential of albiglutide, a long-Acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32:1880-6
    • (2009) Diabetes Care , vol.32 , pp. 1880-1886
    • Rosenstock, J.1    Reusch, J.2    Bush, M.3
  • 20
    • 57349168543 scopus 로고    scopus 로고
    • Pharmacodynamics, pharma-cokinetics, safety, and tolerability of albiglutide, a long-Acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes
    • Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharma-cokinetics, safety, and tolerability of albiglutide, a long-Acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:4810-17
    • (2008) J Clin Endocrinol Metab , vol.93 , pp. 4810-4817
    • Matthews, J.E.1    Stewart, M.W.2    De Boever, E.H.3
  • 21
    • 72549107810 scopus 로고    scopus 로고
    • Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-Acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus
    • Seino Y, Nakajima H, Miyahara H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-Acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin 2009;25:3049-57
    • (2009) Curr Med Res Opin , vol.25 , pp. 3049-3057
    • Seino, Y.1    Nakajima, H.2    Miyahara, H.3
  • 22
    • 79251476847 scopus 로고    scopus 로고
    • Report of the Committee on the classification and diagnostic criteria of diabetes mellitus
    • The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus
    • The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 2010; 1: 212-28
    • (2010) J Diabetes Investig , vol.1 , pp. 212-228
    • Seino, Y.1    Nanjo, K.2
  • 23
    • 0037414781 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis
    • Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003;278:471-8
    • (2003) J Biol Chem , vol.278 , pp. 471-478
    • Li, Y.1    Hansotia, T.2    Yusta, B.3
  • 24
    • 84862299162 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 receptor agonists on body weight: A meta-Analysis
    • Monami M, Dicembrini I, Marchionni N, et al. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-Analysis. Exp Diabetes Res 2012;2012:672658
    • (2012) Exp Diabetes Res , vol.2012 , pp. 672658
    • Monami, M.1    Dicembrini, I.2    Marchionni, N.3
  • 25
    • 84859003663 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-Analyses of randomised controlled trials
    • Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-Analyses of randomised controlled trials. BMJ 2012;344:d7771
    • (2012) BMJ , vol.344
    • Vilsboll, T.1    Christensen, M.2    Junker, A.E.3
  • 26
    • 84856000294 scopus 로고    scopus 로고
    • GLP-1, the gut-brain, and brain-periphery axes
    • Cabou C, Burcelin R. GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud 2011;8:418-31
    • (2011) Rev Diabet Stud , vol.8 , pp. 418-431
    • Cabou, C.1    Burcelin, R.2
  • 27
    • 80053617078 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial
    • Seino Y, Rasmussen MF, Nishida T, et al. Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: results of a 52-week, randomized, multicenter trial. J Diabetes Investig 2011;2:280-6
    • (2011) J Diabetes Investig , vol.2 , pp. 280-286
    • Seino, Y.1    Rasmussen, M.F.2    Nishida, T.3
  • 28
    • 34249869806 scopus 로고    scopus 로고
    • Liraglutide, a long-Acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
    • Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-Acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10
    • (2007) Diabetes Care , vol.30 , pp. 1608-1610
    • Vilsboll, T.1    Zdravkovic, M.2    Le-Thi, T.3
  • 29
    • 84857045922 scopus 로고    scopus 로고
    • The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide
    • Kanoski SE, Rupprecht LE, Fortin SM, et al. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 2012;62:1916-27
    • (2012) Neuropharmacology , vol.62 , pp. 1916-1927
    • Kanoski, S.E.1    Rupprecht, L.E.2    Fortin, S.M.3
  • 30
    • 77950228684 scopus 로고    scopus 로고
    • Glucagon-like pep-tide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation
    • Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like pep-tide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151: 1473-86
    • (2010) Endocrinology , vol.151 , pp. 1473-1486
    • Knudsen, L.B.1    Madsen, L.W.2    Andersen, S.3
  • 31
    • 67649304917 scopus 로고    scopus 로고
    • Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exena-tide or sitagliptin compared to metformin or glyburide
    • Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exena-tide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
    • (2009) Curr Med Res Opin , vol.25 , pp. 1019-1027
    • Dore, D.D.1    Seeger, J.D.2    Arnold Chan, K.3
  • 32
    • 84900833895 scopus 로고    scopus 로고
    • Guidance for Industry. Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research [Last accessed 29 October 2013]
    • Guidance for Industry. Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2008. Available at: http://www.fda.gov/ downloads/drugs/guidancecomplianceregulatoryinformation/guidance/ucm071627.pdf [Last accessed 29 October 2013]
    • (2008)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.